News
- Author:
- Neil Osterweil
Publish date: July 19, 2017
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful” acti...
News
- Author:
- Neil Osterweil
Publish date: July 14, 2017
MADRID – For older patients with AML, there are few good therapeutic options ... until now.
News
- Author:
- Neil Osterweil
Publish date: July 12, 2017
Steps need to be taken to mitigate the risk of cytokine release syndrome and neurologic events and the potential for secondary malignancies.
News
- Author:
- Neil Osterweil
Publish date: July 11, 2017
MADRID – Durable complete responses were associated with overall survival of greater than 8 months.
News
- Author:
- Neil Osterweil
Publish date: July 11, 2017
LUGANO, SWITZERLAND – New PI3K inhibitor promises better safety and efficacy for ongoing treatment.
News
- Author:
- Neil Osterweil
Publish date: July 7, 2017
LUGANO, SWITZERLAND - Patients most likely to respond to tazemetostat were those with activating mutations in EZH2 and MYD88.
News
- Author:
- Neil Osterweil
Publish date: June 27, 2017
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%, consisting...
News
- Author:
- Neil Osterweil
Publish date: June 26, 2017
MADRID – Not seeing the responses you want in BCP-ALL? There may be a predictable reason.
News
- Author:
- Neil Osterweil
Publish date: June 26, 2017
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed follic...
News
- Author:
- Neil Osterweil
Publish date: June 25, 2017
MADRID - Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of n...
News
- Author:
- Neil Osterweil
Publish date: June 25, 2017
Production of fetal hemoglobin is protective against symptoms of these diseases.
News
- Author:
- Neil Osterweil
Publish date: June 24, 2017
MADRID – Talk about versatility: Ibrutinib (Imbruvica), a drug with marked activity against B-cell malignancies, also appears to be a safe and acce...
News
- Author:
- Neil Osterweil
Publish date: June 24, 2017
Good news for patients taking this very toxic chemotherapy regimen.
News
- Author:
- Neil Osterweil
Publish date: June 24, 2017
Anticoagulation should be considered, carefully, on a patient-by-patient basis.
News
- Author:
- Neil Osterweil
Publish date: June 23, 2017
MADRID – Leukemia may have a previously unconsidered cause in some patients.
